▼ -60.20% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Cassava Sciences in the last 3 months. The average price target is $19.33, with a high forecast of $24.00 and a low forecast of $14.00. The average price target represents a -60.20% upside from the last price of $48.58.
The current consensus among 3 contributing investment analysts is to buy stock in Cassava Sciences.
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for nervous system disorders. Its lead therapeutic product candidate is PTI-125, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.